A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLS5308 Monotherapy in Participants With Advanced Solid Tumors
Latest Information Update: 16 Mar 2026
At a glance
- Drugs QLS 5308 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 16 Mar 2026 New trial record